Open-label Study of Surufatinib in Japanese Patients
brief summary
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.
detailed description
The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in Japanese patients.
The study will be conducted in 2 parts:
* Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the recommended clinical dose in Japanese patients with nonhematologic malignancies * Part 2 - evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs
All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.
official title
An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors